Top Markets
Coin of the day
Mithra Pharmaceuticals S.A. Mithra Pharmaceuticals S.A.

Mithra Pharmaceuticals S.A.

MITRA
株式のランク #30359
Mithra Pharmaceuticals SA, established in 1999 and headquartered in Liège,... Mithra Pharmaceuticals SA, established in 1999 and headquartered in Liège, Belgium, specializes in the creation, production, and worldwide commercialization of advanced therapeutic solutions. The company's core focus areas include contraception, the management of menopause, and treatments for hormone-dependent cancers. Its robust development pipeline features Estelle, a combined oral contraceptive that has successfully concluded Phase III clinical trials, and Donesta, an estetrol-based oral hormone treatment currently undergoing Phase III development for menopausal symptoms. Mithra's product portfolio also encompasses Myring, a hormonal contraceptive vaginal ring; Tibelia, a therapy designed to address both menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant targeting prostate and breast cancers, as well as various benign gynecological conditions. Furthermore, the company markets NEXTSTELLIS, an established oral contraceptive pill. Their offerings span diverse pharmaceutical formats, including polymeric devices, implants, sterile injectable medications, and hormonal tablets.
株価
$0.25620952
最終同期: 2024-07-23
時価総額
$17.14M
変化(1日)
10.83%
変化(1年)
0.00%
BE
取引 Mithra Pharmaceuticals S.A. (MITRA)

カテゴリー

Mithra Pharmaceuticals S.A.(MITRA)のP/S比率
2026 時点のP/S比率 TTM: 0
Mithra Pharmaceuticals S.A. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0 です。2026 年末時点でのP/S比率は 0 でした。
Mithra Pharmaceuticals S.A. の P/S 比率の履歴(2026 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
提供された日付のデータは十分ではありません。